A Phase 1 interventional study of BMS-986533 and Famotidine in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-24.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the safety and pharmacokinetics of BMS-986533 in healthy participants receiving single and multiple doses, to assess food and pH effects on the relative bioavailability of BMS-986533, and the P-gp and BCRP-mediated drug-drug interaction potential of the study drug
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-986533 · Drug: Placebo
Drug: BMS-986533 · Drug: Placebo
Drug: BMS-986533 · Drug: Famotidine
Drug: BMS-986533 · Drug: Dabigatran Etexilate · Drug: Rosuvastatin
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Number of participants with Adverse Events (AE)
Time frame: Up to Day 47
Number of participants with Serious Adverse Events (SAE)
Time frame: Up to Day 47
Number of participants with Vital Sign Abnormalities
Time frame: Up to Day 27
Number of participants with Physical Examination Abnormalities
Including neurological examination
Time frame: Up to Day 27
Number of participants with Electrocardiogram (ECG) Abnormalities
Time frame: Up to Day 27
Number of participants with Clinical Laboratory Assessments Abnormalities
Time frame: Up to Day 27
Number of participants with Treatment-emergent suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Time frame: Up to Day 27
Maximum observed concentration (Cmax)
Time frame: Up to Day 26 from last dose
Time of maximum observed concentration (Tmax)
Time frame: Up to Day 26 from last dose
Area under the concentration-time curve from Time Zero to Time of Last Quantifiable Concentration (AUC(0-T))
Arm A, Arm B, and Arm C
Time frame: Up to Day 26 from last dose
AUC from Time Zero Extrapolated to Infinite Time (AUC(INF))
Arm A and Arm C
Time frame: Up to Day 26 from last dose
AUC from Time Zero to 24 Hours (AUC(0-24))
Arm A
Time frame: Up to Day 9 from last dose
Elimination Half-Life (T-HALF)
Arm A, Arm B, and Arm C
Time frame: Up to Day 26 from last dose
Apparent Total Body Clearance from Plasma (CLT/F)
Arm A, Arm B, and Arm C
Time frame: Up to Day 26 from last dose
Apparent Volume of Distribution (Vz/F)
Arm A, Arm B, and Arm C
Time frame: Up to Day 26 from last dose
AUC in 1 dosing interval (AUC (TAU))
Arm B, D
Time frame: Up to Day 22 from last dose
Cerebrospinal fluid (CSF) concentrations
Arm B
Time frame: Up to Day 13
Ratio of total and unbound CSF to plasma concentration
Arm B
Time frame: Up to Day 13
Geometric mean ratio of Cmax
Arm C, D
Time frame: Up to Day 26 from last dose
Geometric mean ratio of AUC(0-T)
Arm C, D
Time frame: Up to Day 26 from last dose
Geometric mean ratio of AUC(INF)
Arm C, D
Time frame: Up to Day 26 from last dose
Cmax of dabigatran in plasma
Arm D
Time frame: Up to Day 18 from last dose
Cmax of rosuvastatin in plasma
Arm D
Time frame: Up to Day 20 from last dose
AUC(0-T) of dabigatran in plasma
Arm D
Time frame: Up to Day 18 from last dose
AUC(0-T) of rosuvastatin in plasma
Arm D
Time frame: Up to Day 20 from last dose
AUC(INF) of dabigatran in plasma
Arm D
Time frame: Up to Day 18 from last dose
AUC(INF) of rosuvastatin in plasma
Arm D
Time frame: Up to Day 20 from last dose
Tmax of dabigatran in plasma
Arm D
Time frame: Up to Day 18 from last dose
Tmax of rosuvastatin in plasma
Arm D
Time frame: Up to Day 20 from last dose
T-HALF of dabigatran in plasma
Time frame: Up to Day 26 from last dose
T-HALF of rosuvastatin in plasma
Arm D
Time frame: Up to Day 20 from last dose
CLT/F of dabigatran in plasma
Arm D
Time frame: Up to Day 18 from last dose
CLT/F of rosuvastatin in plasma
Time frame: Up to Day 27 from last dose
Vz/F of dabigatran in plasma
Arm D
Time frame: Up to Day 18 from last dose
Vz/F of rosuvastatin in plasma
Arm D
Time frame: Up to Day 20 from last dose
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Started Jul 2026 (actual). Primary completion is estimated for Jun 2027, 10 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lecithin Cholesterol Acyltransferase Deficiency